Spero Therapeutics Inc (SPRO)

$1.43

+0.01

(+0.7%)▲

Market is closed - opens 7 PM, 04 Jun 2024

Insights on Spero Therapeutics Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 71.82M → 4.20M (in $), with an average decrease of 94.2% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 51.19M → -12.66M (in $), with an average decrease of 124.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 72.6% return, outperforming this stock by 94.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 235.1% return, outperforming this stock by 325.0%

Performance

  • $1.40
    $1.43
    $1.43
    downward going graph

    2.1%

    Downside

    Day's Volatility :2.1%

    Upside

    0.0%

    downward going graph
  • $0.99
    $1.89
    $1.43
    downward going graph

    30.77%

    Downside

    52 Weeks Volatility :47.62%

    Upside

    24.34%

    downward going graph

Returns

PeriodSpero Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-14.37%
-1.0%
0.0%
6 Months
16.26%
9.6%
0.0%
1 Year
-19.21%
11.0%
0.0%
3 Years
-89.94%
18.5%
-22.6%

Highlights

Market Capitalization
75.9M
Book Value
$1.79
Earnings Per Share (EPS)
0.44
PE Ratio
3.19
PEG Ratio
0.0
Wall Street Target Price
7.5
Profit Margin
21.09%
Operating Margin TTM
-150.88%
Return On Assets TTM
12.06%
Return On Equity TTM
29.06%
Revenue TTM
111.0M
Revenue Per Share TTM
2.1
Quarterly Revenue Growth YOY
347.90000000000003%
Gross Profit TTM
-42.1M
EBITDA
27.4M
Diluted Eps TTM
0.44
Quarterly Earnings Growth YOY
0.75
EPS Estimate Current Year
-1.27
EPS Estimate Next Year
-1.2
EPS Estimate Current Quarter
-0.04
EPS Estimate Next Quarter
-0.44

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Spero Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 424.48%

Current $1.43
Target $7.50

Technicals Summary

Sell

Neutral

Buy

Spero Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Spero Therapeutics Inc
Spero Therapeutics Inc
-13.86%
16.26%
-19.21%
-89.94%
-86.59%
Moderna, Inc.
Moderna, Inc.
21.03%
85.08%
14.68%
-28.27%
659.22%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
3.22%
20.18%
31.88%
93.3%
227.58%
Novo Nordisk A/s
Novo Nordisk A/s
8.85%
34.38%
71.83%
235.07%
463.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
16.81%
34.1%
40.6%
123.97%
174.53%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Spero Therapeutics Inc
Spero Therapeutics Inc
3.19
3.19
0.0
-1.27
0.29
0.12
NA
1.79
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.14
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
28.89
28.89
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
46.97
46.97
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.59
29.59
0.53
17.08
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Spero Therapeutics Inc
Spero Therapeutics Inc
Buy
$75.9M
-86.59%
3.19
21.09%
Moderna, Inc.
Moderna, Inc.
Buy
$54.6B
659.22%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.0B
227.58%
28.89
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$602.6B
463.44%
46.97
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$117.5B
174.53%
29.59
39.46%

Institutional Holdings

  • Anson Funds Management LP

    7.97%

  • Vanguard Group Inc

    3.07%

  • ADAR1 Capital Management LLC

    1.98%

  • Alphabet Inc

    1.65%

  • Murchinson Ltd.

    1.60%

  • Acadian Asset Management LLC

    1.42%

Company Information

spero therapeutics is focused on the development of novel therapies to treat highly resistant bacterial infections. the culture at spero is one of respect, action, collaboration and transparency. spero team members are leaders in the field, and have the ability and desire to be a part of a team. at spero, a feeling that we are part of something groundbreaking and innovative fuels our approach.

Organization
Spero Therapeutics Inc
Employees
46
CEO
Dr. Ankit Mahadevia M.D., MBA
Industry
Health Technology

Discover More

FAQs